Target intelligence / Profile preview

Progesterone receptor membrane component 2 (PGRMC2)

Target
PGRMC2
Molecular classification
Receptor (membrane-associated), Heme-binding protein, Non-classical steroid receptor, Intracellular heme chaperone
01

Overview

Progesterone receptor membrane component 2 (PGRMC2) is an evolutionarily conserved membrane-associated protein that acts as a non-classical receptor for progesterone and a heme chaperone, playing essential roles in the regulation of uterine architecture and reproductive lifespan. PGRMC2 localizes predominantly to uterine epithelia and ovarian cells, where it modulates cell cycle progression, apoptosis, and steroid responses independently of the classical nuclear progesterone receptor. Its expression is altered in several gynecological diseases, including endometriosis, infertility, and select cancers, suggesting roles as a therapeutic target or biomarker. Experimental ligands such as CPAG-1 have shown preclinical protective roles in ischemic injury, although direct drug interactions in clinical use remain largely unexplored. The molecular mechanisms further involve heme trafficking to the nucleus for regulation of transcriptional repressors impacting metabolism and cell function.

Other names
PGRMC2Membrane-associated progesterone receptor family memberDg6
02

Mechanism of action

Ligand (such as CPAG-1) promotes neuroprotection via PGRMC2 activation; PGRMC2 influences progesterone-dependent suppression of cell mitosis/apoptosis; Delivers signaling heme for transcriptional regulation

03

Biological functions

Maintenance of uterine histoarchitectureRegulation of cell cycle (mitosis, apoptosis)Adipose tissue developmentRegulation of glucose homeostasisDelivery of signaling heme to the nucleusModulation of progesterone signaling independent from classical nuclear receptor
04

Disease associations

Cancer (ovarian, endometrial)Infertility and reproductive dysfunctionsEndometriosisAchalasia-Addisonianism-Alacrima SyndromeIschemic stroke (protective actions in preclinical models)
05

Safety considerations

Disruption in uterine/reproductive tissue architectureAberrant proliferation and apoptosis in ovary leading to infertility or hyperplasiaInsufficient knowledge to assess systemic safety for clinical targeting
06

Interacting drugs

CPAG-1 (experimental ligand in ischemic stroke model)

1 more in the full profile.

07

Biomarkers

PGRMC2 expression may be a biomarker in endometriosis, diminished ovarian reserve, and certain reproductive cancers

Beyond the preview

Go deeper on Progesterone receptor membrane component 2 (PGRMC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progesterone receptor membrane component 2 (PGRMC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call